Caladrius Biosciences to Present at Upcoming June Conferences
BASKING RIDGE, N.J., June 1, 2016 – Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that the Company’s leadership and experts will present at the following upcoming June conferences:
LD Micro Invitational
Date and Time: June 7, 2016, 8 AM PDT
Website: www.events.ldmicro.com
Venue: Luxe Sunset Bel Air, Los Angeles, California
Topic: Company presentation
Presenter: David J. Mazzo, PhD, Chief Executive Officer
ISSCR 2016 Annual Meeting
Date and Time: June 22, 2016, 7:30 PM PDT
Website: www.isscr.org/home/annual-meeting/san-francisco-2016
Venue: Moscone West, San Francisco, California
Poster Topic: CD34+CD45- Cells Isolated From Human Blood Have Molecular and Functional Characteristics of Endothelial Progenitors
Poster Presenter(s): Yajuan Jiang, PhD, Senior Scientist, Associate Director, PCT; David O’Neill, MD, Medical Director and Director, Analytical Development, PCT
Poster To Be Archived At: www.caladrius.com/ISSCR2016poster
About Caladrius Biosciences
Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co., Ltd. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. Around the core expertise of PCT, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit www.caladrius.com.
